Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:OXB
- CUSIP: N/A
- Web: www.oxfordbiomedica.co.uk
- Market Cap: £265.39 million
- Outstanding Shares: 3,040,000,000
- 50 Day Moving Avg: GBX 8.92
- 200 Day Moving Avg: GBX 5.90
- 52 Week Range: GBX 2.98 - GBX 11.50
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: £30.99 million
- Price / Sales: 8.56
- Book Value: N/A
- Price / Book: N/A
- EBIDTA: ($2,220,000.00)
- Net Margins: -47.43%
- Return on Equity: -132.12%
- Return on Assets: -26.08%
- Average Volume: 11.79 million shs.
Frequently Asked Questions for Oxford BioMedica plc (LON:OXB)
What is Oxford BioMedica plc's stock symbol?
Oxford BioMedica plc trades on the London Stock Exchange (LON) under the ticker symbol "OXB."
Where is Oxford BioMedica plc's stock going? Where will Oxford BioMedica plc's stock price be in 2017?
2 analysts have issued twelve-month price objectives for Oxford BioMedica plc's stock. Their predictions range from GBX 8.70 to GBX 13. On average, they anticipate Oxford BioMedica plc's share price to reach GBX 10.85 in the next twelve months. View Analyst Ratings for Oxford BioMedica plc.
Who are some of Oxford BioMedica plc's key competitors?
Some companies that are related to Oxford BioMedica plc include Seres Therapeutics (MCRB), Audentes Therapeutics (BOLD), Aurinia Pharmaceuticals (AUPH), Ignyta (RXDX), CytomX Therapeutics (CTMX), Calithera Biosciences (CALA), Intra-Cellular Therapies (ITCI), Sucampo Pharmaceuticals (SCMP), Jounce Therapeutics (JNCE), AnaptysBio (ANAB), NantKwest (NK), Atara Biotherapeutics (ATRA), Progenics Pharmaceuticals (PGNX), Karyopharm Therapeutics (KPTI), MERSANA THERPTS (MRSN), AVEO Pharmaceuticals (AVEO), Adaptimmune Therapeutics PLC (ADAP) and GlycoMimetics (GLYC).
Who are Oxford BioMedica plc's key executives?
Oxford BioMedica plc's management team includes the folowing people:
- John Dawson, Chief Executive Officer, Executive Director
- Tim Watts, Chief Financial Officer, Company Secretary, Executive Director
- Peter Nolan, Executive Director, Chief Business Officer
- Lorenzo Tallarigo M.D., Non-Executive Chairman of the Board
- Andrew J. Heath M.D., Ph.D., Non-Executive Deputy Chairman of the Board, Senior Independent Director
- Martin Diggle, Non-Executive Director
- Stuart Henderson, Non-Executive Director
How do I buy Oxford BioMedica plc stock?
Shares of Oxford BioMedica plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Oxford BioMedica plc's stock price today?
MarketBeat Community Rating for Oxford BioMedica plc (LON OXB)MarketBeat's community ratings are surveys of what our community members think about Oxford BioMedica plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Oxford BioMedica plc stock can currently be purchased for approximately GBX 8.73.
Consensus Ratings for Oxford BioMedica plc (LON:OXB) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 1 Buy Rating|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||GBX 10.85|
Analysts' Ratings History for Oxford BioMedica plc (LON:OXB)
(Data available from 8/20/2015 forward)
|7/27/2017||N+1 Singer||Boost Price Target||Hold||GBX 7.80 -> GBX 8.70|
|7/13/2017||Shore Capital||Reiterated Rating||not rated|
|7/13/2017||Jefferies Group LLC||Reiterated Rating||Buy||GBX 13|
Earnings History for Oxford BioMedica plc (LON:OXB)Earnings History by Quarter for Oxford BioMedica plc (LON OXB)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Oxford BioMedica plc (LON:OXB)
Current Year EPS Consensus Estimate: $-0.21 EPS
Dividend History for Oxford BioMedica plc (LON:OXB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Oxford BioMedica plc (LON:OXB)Insider Trades by Quarter for Oxford BioMedica plc (LON:OXB)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/17/2017||Peter Nolan||Insider||Buy||249,687||GBX 8||£19,974.96|
|7/13/2017||Martin Diggle||Insider||Buy||660,000||GBX 9||£59,400|
|6/23/2017||Lorenzo Tallarigo||Insider||Buy||49,033||GBX 5||£2,451.65|
|5/24/2017||Lorenzo Tallarigo||Insider||Buy||53,260||GBX 5||£2,663|
|4/24/2017||Lorenzo Tallarigo||Insider||Buy||54,090||GBX 5||£2,704.50|
|3/23/2017||Lorenzo Tallarigo||Insider||Buy||49,468||GBX 5||£2,473.40|
|2/24/2017||Lorenzo Tallarigo||Insider||Buy||67,165||GBX 4||£2,686.60|
|12/15/2016||Lorenzo Tallarigo||Insider||Buy||65,993||GBX 4||£2,639.72|
|11/25/2016||Lorenzo Tallarigo||Insider||Buy||75,417||GBX 4||£3,016.68|
|10/25/2016||Lorenzo Tallarigo||Insider||Buy||77,864||GBX 3||£2,335.92|
|9/26/2016||Lorenzo Tallarigo||Insider||Buy||79,988||GBX 3||£2,399.64|
|8/25/2016||Tallarigo ,Lorenzo||Insider||Buy||62,257||GBX 4||£2,490.28|
|7/25/2016||Tallarigo ,Lorenzo||Insider||Buy||63,351||GBX 4||£2,534.04|
|6/24/2016||Tallarigo ,Lorenzo||Insider||Buy||62,847||GBX 4||£2,513.88|
|5/13/2016||Diggle ,Martin||Insider||Buy||42,072||GBX 5||£2,103.60|
|5/12/2016||Diggle ,Martin||Insider||Buy||45,428||GBX 5||£2,271.40|
|5/5/2016||Diggle ,Martin||Insider||Buy||12,500||GBX 6||£750|
|5/4/2016||Diggle ,Martin||Insider||Buy||44,689||GBX 6||£2,681.34|
|5/3/2016||Diggle ,Martin||Insider||Buy||317,382||GBX 6||£19,042.92|
|4/22/2016||Tallarigo ,Lorenzo||Insider||Buy||41,083||GBX 6||£2,464.98|
|3/24/2016||Tallarigo ,Lorenzo||Insider||Buy||41,550||GBX 6||£2,493|
|2/26/2016||Diggle ,Martin||Insider||Buy||29,345||GBX 7||£2,054.15|
|2/25/2016||Tallarigo ,Lorenzo||Insider||Buy||36,370||GBX 7||£2,545.90|
|2/24/2016||Diggle ,Martin||Insider||Buy||46,693||GBX 6||£2,801.58|
|7/1/2015||Diggle ,Martin||Insider||Buy||284,439||GBX 0.09||£256|
|6/30/2015||Diggle ,Martin||Insider||Buy||775,000||GBX 0.09||£697.50|
|6/19/2015||Diggle ,Martin||Insider||Buy||225,000||GBX 0.08||£180|
|6/12/2015||Martin Diggle||Insider||Buy||283,978||GBX 9.01||£25,586.42|
|6/11/2015||Martin Diggle||Insider||Buy||416,022||GBX 9||£37,441.98|
|6/9/2015||Daniel Soland||Insider||Buy||500,000||GBX 9.45||£47,250|
|5/21/2015||Andrew Heath||Insider||Buy||100,000||GBX 10.60||£10,600|
|5/19/2015||Tim Watts||Insider||Buy||194,174||GBX 10.30||£19,999.92|
Headline Trends for Oxford BioMedica plc (LON:OXB)
Latest Headlines for Oxford BioMedica plc (LON:OXB)
Oxford BioMedica plc (OXB) Chart for Sunday, August, 20, 2017